Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis

Medicine (Baltimore) · 2023 · PMC10659694

Europe PMC

hedged sentence

0.2600

closest p · 5.2× alpha

0.2600

boldest claim

The sentences

did not reach statistical significanceP = .26not close (p > 0.1)

It was observed that the DCR for HR+ breast cancer in the NCET group was slightly higher than that in the NCT/NET group, but the difference did not reach statistical significance [RR = 1.12, 95% CI (0.92, 1.35), Z = 1.12, P = .26] (Fig. 5 A).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.